{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:45:39Z","timestamp":1780472739544,"version":"3.54.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:00:00Z","timestamp":1611705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100002296","name":"De Reuter Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objective of this study was to analyse the predictive value of anti-carbamylated protein (anti-CarP) and anti-peptidyl-arginine deiminase type-3 (anti-PAD3) antibodies, alone or in combination with RF and ACPA, to identify patients at high risk of developing severe RA outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients within the Swiss Clinical Quality Management registry with a biobank sample were tested for RF, ACPA, anti-CarP, and anti-PAD3 antibodies. We examined the association of each autoantibody with DAS28, HAQ and radiographic damage (Ratingen) at baseline and longitudinally.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analyses included 851 established RA patients and 516 disease controls [axial spondyloarthritis (axSpA\u2009=\u2009320) and PsA (196)]. Anti-CarP and anti-PAD3 antibodies were, respectively, present in 22.4% and 10.7% of the whole RA population, and in 13.2% and 3.8% of the RF and ACPA double seronegative patients. At baseline, RA patients with anti-PAD3 had higher DAS28 (4.2 vs 3.7; P= 0.005) and significantly more radiographic damage (14.9 vs 8.8; P= 0.02) than anti-PAD3-negative patients. In the ACPA-negative subgroup, baseline Ratingen scores were significantly higher in anti-PAD3-positive patients (P= 0.01). The combination of anti-PAD3, RF IgM, and ACPA was associated with significantly higher baseline radiographic scores than the double seropositive group (P= 0.04). The presence of any two of the previous autoantibodies was associated with significantly greater radiographic progression over 10\u2009years than if all were absent (P= 0.02). There were no differences in RA outcome measures with regards to anti-CarP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anti-PAD3 antibodies are associated with higher disease activity and joint damage scores in RA patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab050","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T20:23:49Z","timestamp":1611001429000},"page":"4598-4608","source":"Crossref","is-referenced-by-count":19,"title":["Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA for the severity of rheumatoid arthritis"],"prefix":"10.1093","volume":"60","author":[{"given":"Celine","family":"Lamacchia","sequence":"first","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1956-2607","authenticated-orcid":false,"given":"Delphine S","family":"Courvoisier","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Jarlborg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvette","family":"Bas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Roux-Lombard","sequence":"additional","affiliation":[{"name":"Department of Immunology and Allergy, Geneva University Hospital, Geneva"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"M\u00f6ller","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Immunology and Allergy, Bern University Hospital, Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-7132","authenticated-orcid":false,"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zurich University Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Bentow","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Martinez-Prat","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mahler","sequence":"additional","affiliation":[{"name":"Research and Development, Inova Diagnostics, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Gabay","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SCQM Rheumatologists","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,27]]},"reference":[{"key":"2021100217531107000_keab050-B1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fmed.2018.00339","article-title":"The clinical value of autoantibodies in rheumatoid arthritis","volume":"5","author":"Bugatti","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2021100217531107000_keab050-B2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1155\/2013\/726598","article-title":"Rheumatoid factors: clinical applications","volume":"35","author":"Ingegnoli","year":"2013","journal-title":"Dis Markers"},{"key":"2021100217531107000_keab050-B4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/ard.2005.041376","article-title":"Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset","volume":"65","author":"Berglin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021100217531107000_keab050-B5","first-page":"301","article-title":"IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications","volume":"14","author":"Jorgensen","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2021100217531107000_keab050-B6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann Intern Med"},{"key":"2021100217531107000_keab050-B7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42358-018-0042-8","article-title":"Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis","volume":"59","author":"de Brito Rocha","year":"2019","journal-title":"Adv Rheumatol"},{"key":"2021100217531107000_keab050-B8","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s10067-017-3684-8","article-title":"Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays","volume":"36","author":"Vos","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2021100217531107000_keab050-B9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24827","article-title":"Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.autrev.2009.04.006","article-title":"Anti-citrullinated protein\/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis","volume":"9","author":"Szodoray","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2021100217531107000_keab050-B11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1172\/JCI1316","article-title":"Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis\u2013specific autoantibodies","volume":"101","author":"Schellekens","year":"1998","journal-title":"J Clin Invest"},{"key":"2021100217531107000_keab050-B12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12016-007-8030-5","article-title":"Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients","volume":"34","author":"Correia","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021100217531107000_keab050-B13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/acr.23497","article-title":"Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward","volume":"70","author":"Boer","year":"2018","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2021100217531107000_keab050-B14","doi-asserted-by":"crossref","first-page":"17372","DOI":"10.1073\/pnas.1114465108","article-title":"Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage","volume":"108","author":"Shi","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021100217531107000_keab050-B15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.37830","article-title":"Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis","volume":"65","author":"Shi","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/annrheumdis-2013-205109","article-title":"Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies","volume":"73","author":"Jiang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021100217531107000_keab050-B17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/annrheumdis-2015-208870","article-title":"The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor","volume":"76","author":"Ajeganova","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021100217531107000_keab050-B18","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1002\/art.40237","article-title":"Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR Cohort","volume":"69","author":"Truchetet","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021100217531107000_keab050-B19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12026-014-8560-x","article-title":"Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis","volume":"61","author":"Yee","year":"2015","journal-title":"Immunol Res"},{"key":"2021100217531107000_keab050-B20","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s10067-019-04616-z","article-title":"Diagnostic and prognostic value of anti-CarP antibodies in a sample of Egyptian rheumatoid arthritis patients","volume":"38","author":"Elsayed","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2021100217531107000_keab050-B21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.40562","article-title":"Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals","volume":"70","author":"Verheul","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021100217531107000_keab050-B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-015-0536-2","article-title":"Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage","volume":"17","author":"Brink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021100217531107000_keab050-B23","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","article-title":"Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis","volume":"73","author":"Shi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021100217531107000_keab050-B24","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3389\/fimmu.2018.02696","article-title":"Autoantibodies to peptidylarginine deiminase 2 are associated with less severe disease in rheumatoid arthritis","volume":"9","author":"Darrah","year":"2018","journal-title":"Front Immunol"},{"key":"2021100217531107000_keab050-B25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2007.080267","article-title":"Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity","volume":"67","author":"Halvorsen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021100217531107000_keab050-B26","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/art.23596","article-title":"Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis","volume":"58","author":"Harris","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2008.094490","article-title":"Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents","volume":"68","author":"Halvorsen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021100217531107000_keab050-B28","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.27570","article-title":"Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis","volume":"62","author":"Kolfenbach","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B29","doi-asserted-by":"crossref","first-page":"186ra165","DOI":"10.1126\/scitranslmed.3005370","article-title":"Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity","volume":"5","author":"Darrah","year":"2013","journal-title":"Sci Transl Med"},{"key":"2021100217531107000_keab050-B30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13075-016-1126-7","article-title":"Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans","volume":"18","author":"Navarro-Millan","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021100217531107000_keab050-B31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.autrev.2016.03.016","article-title":"Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis","volume":"15","author":"Seaman","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2021100217531107000_keab050-B32","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3899\/jrheum.130767","article-title":"Physicians of the Swiss Clinical Quality Management Program for Rheumatoid A. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?","volume":"41","author":"Ciubotariu","year":"2014","journal-title":"J Rheumatol"},{"key":"2021100217531107000_keab050-B33","first-page":"2094","article-title":"A new method of scoring radiographic change in rheumatoid arthritis","volume":"25","author":"Rau","year":"1998","journal-title":"J Rheumatol"},{"key":"2021100217531107000_keab050-B34","first-page":"682","article-title":"Comparison of the Rau method and the Larsen method in the evaluation of radiographic progression in early rheumatoid arthritis","volume":"29","author":"Tanaka","year":"2002","journal-title":"J Rheumatol"},{"key":"2021100217531107000_keab050-B35","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2021100217531107000_keab050-B36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09638289209167073","article-title":"Validity and discriminant ability of the HAQ Functional Index in early rheumatoid arthritis","volume":"14","author":"Guillemin","year":"1992","journal-title":"Disabil Rehabil"},{"key":"2021100217531107000_keab050-B37","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/art.22983","article-title":"Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation","volume":"56","author":"Foulquier","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13075-018-1533-z","article-title":"Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis","volume":"20","author":"Cappelli","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021100217531107000_keab050-B39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13075-015-0638-x","article-title":"Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis","volume":"17","author":"Kokkonen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2021100217531107000_keab050-B40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13075-016-1014-1","article-title":"Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking","volume":"18","author":"Roos","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021100217531107000_keab050-B41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/art.40791","article-title":"Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis","volume":"71","author":"Darrah","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2021100217531107000_keab050-B42","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0140-6736(15)60359-2","article-title":"Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register","volume":"385","author":"Humphreys","year":"2015","journal-title":"Lancet"},{"key":"2021100217531107000_keab050-B43","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B44","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nm1637","article-title":"Protein carbamylation links inflammation, smoking, uremia and atherogenesis","volume":"13","author":"Wang","year":"2007","journal-title":"Nat Med"},{"key":"2021100217531107000_keab050-B45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.autrev.2015.08.003","article-title":"Auto-reactions, autoimmunity and psoriatic arthritis","volume":"14","author":"Chimenti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2021100217531107000_keab050-B46","first-page":"1","article-title":"Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases","volume":"00","author":"Sidiras","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2021100217531107000_keab050-B47","first-page":"1002","article-title":"Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides","volume":"35","author":"Innala","year":"2008","journal-title":"J Rheumatol"},{"key":"2021100217531107000_keab050-B48","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/art.24716","article-title":"Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis","volume":"60","author":"van der Linden","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021100217531107000_keab050-B49","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fimmu.2018.01113","article-title":"Comparison of serological biomarkers in rheumatoid arthritis and their combination to improve diagnostic performance","volume":"9","author":"Martinez-Prat","year":"2018","journal-title":"Front Immunol"},{"key":"2021100217531107000_keab050-B50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.2006.058933","article-title":"Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not?","volume":"66","author":"Vannini","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab050\/36123974\/keab050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4598\/40500542\/keab050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4598\/40500542\/keab050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T18:03:25Z","timestamp":1633197805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/10\/4598\/6121325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,10,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab050","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,1,27]]}}}